SNSE vs. XGN, CTSO, EPRX, TPST, VACC, ACRS, ANVS, GNLX, LABP, and BNTC
Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Exagen (XGN), Cytosorbents (CTSO), Eupraxia Pharmaceuticals (EPRX), Tempest Therapeutics (TPST), Vaccitech (VACC), Aclaris Therapeutics (ACRS), Annovis Bio (ANVS), Genelux (GNLX), Landos Biopharma (LABP), and Benitec Biopharma (BNTC). These companies are all part of the "medical" sector.
Exagen (NASDAQ:XGN) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
Exagen has higher revenue and earnings than Sensei Biotherapeutics. Exagen is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sensei Biotherapeutics had 2 more articles in the media than Exagen. MarketBeat recorded 4 mentions for Sensei Biotherapeutics and 2 mentions for Exagen. Sensei Biotherapeutics' average media sentiment score of 0.44 beat Exagen's score of 0.11 indicating that Exagen is being referred to more favorably in the media.
Sensei Biotherapeutics has a net margin of 0.00% compared to Sensei Biotherapeutics' net margin of -34.74%. Exagen's return on equity of -46.67% beat Sensei Biotherapeutics' return on equity.
Sensei Biotherapeutics received 5 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 78.13% of users gave Sensei Biotherapeutics an outperform vote while only 54.05% of users gave Exagen an outperform vote.
Exagen currently has a consensus price target of $7.00, suggesting a potential upside of 258.97%. Sensei Biotherapeutics has a consensus price target of $4.50, suggesting a potential upside of 508.44%. Given Exagen's higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Exagen.
75.3% of Exagen shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 26.1% of Exagen shares are held by company insiders. Comparatively, 25.5% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Exagen has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Sensei Biotherapeutics has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.
Summary
Exagen beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.
Get Sensei Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensei Biotherapeutics Competitors List
Related Companies and Tools
